Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Eli Lilly ($LLY) surges past $1.07tn as EU oncology win and Medicare GLP-1 program align with analyst upgrade
Eli Lilly NYSE LLY surges 6.3 percent to record $1,208.12 on EU Jaypirca approval, Medicare GLP-1 Bridge Program and Leerink price target raise. Read more.
Could AI-guided TMS give NRx a sharper mental health platform story?
NRx’s HOPE Therapeutics begins Zeta-guided TMS treatments, sharpening NRXP’s precision psychiatry, clinic network and depression care strategy.
Why CGTX stock could draw attention after FDA alignment on DLB psychosis
Cognition Therapeutics’ FDA alignment gives zervimesine a clearer DLB psychosis path, sharpening CGTX’s dementia drug development and stock story.
Could one hair loss antibody make Absci’s AI drug platform harder to ignore?
Absci’s ABS-201 data and $100 million raise sharpen ABSI’s AI biologics story across androgenetic alopecia, endometriosis and platform validation.
Avacta just won a clean FDA path to full AVA6000 approval, so why did $AVCT barely move?
Avacta won a clean FDA path to full AVA6000 approval, yet AVCT (AIM) barely moved. The real question is whether a partner signs before cash runs low.
Could Datroway become AstraZeneca and Daiichi Sankyo’s next major oncology franchise after Enhertu?
atroway has received a positive European regulatory recommendation for first-line treatment of metastatic triple-negative breast cancer in patients unable to receive immunotherapy. The decision moves AstraZeneca PLC and Daiichi Sankyo Company, Limited closer to opening a commercially important market while increasing the strategic value of their antibody drug conjugate partnership.
Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline?
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today!
Could TSHA stock gain momentum as Taysha advances TSHA-102 toward a Rett syndrome BLA?
Find out how Taysha’s TSHA-102 Rett syndrome update could affect TSHA stock, BLA planning and rare disease gene therapy competition today!
Thalia Therapeutics (AIM: THAT) shares jump 17% as Sanmirna deal adds Phase 1 AML asset
Thalia Therapeutics has agreed to acquire Sanmirna Therapeutics and its Phase 1 acute myeloid leukaemia drug miRisten, while raising ÂŁ2.75 million to fund clinical data expected in 2027.
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!